301075 多瑞医药
已收盘 12-25 15:00:00
资讯
新帖
简况
多瑞医药新提交1件商标注册申请
证券之星 · 12-18
多瑞医药新提交1件商标注册申请
多瑞医药最新公告：醋酸钠林格注射液拟中标第十批国家药品集采
证券之星 · 12-16
多瑞医药最新公告：醋酸钠林格注射液拟中标第十批国家药品集采
多瑞医药(301075.SZ)：醋酸钠林格注射液拟中选全国药品集采
智通财经 · 12-16
多瑞医药(301075.SZ)：醋酸钠林格注射液拟中选全国药品集采
多瑞医药（301075）股东西藏嘉康时代科技发展有限公司质押320万股，占总股本4%
证券之星 · 12-06
多瑞医药（301075）股东西藏嘉康时代科技发展有限公司质押320万股，占总股本4%
多瑞医药最新公告：全资子公司收到碳酸氢钠注射液药品注册受理通知书
证券之星 · 11-19
多瑞医药最新公告：全资子公司收到碳酸氢钠注射液药品注册受理通知书
多瑞医药(301075.SZ)：碳酸氢钠注射液药品注册获受理
智通财经 · 11-19
多瑞医药(301075.SZ)：碳酸氢钠注射液药品注册获受理
多瑞医药最新公告：四川前沿艾可宁原料药获批上市并通过药品GMP符合性检查
证券之星 · 11-06
多瑞医药最新公告：四川前沿艾可宁原料药获批上市并通过药品GMP符合性检查
多瑞医药：控股子公司拟收购的四川前沿原料药获批上市
美港电讯 · 11-06
多瑞医药：控股子公司拟收购的四川前沿原料药获批上市
多瑞医药(301075.SZ)拟收购主体四川前沿通过药品GMP符合性检查暨原料药获批上市
智通财经 · 11-06
多瑞医药(301075.SZ)拟收购主体四川前沿通过药品GMP符合性检查暨原料药获批上市
多瑞医药(301075.SZ)拟以6880万元出售湖北天济5.66%股权 回收资金
智通财经 · 11-04
多瑞医药(301075.SZ)拟以6880万元出售湖北天济5.66%股权 回收资金
多瑞医药最新公告：拟转让湖北天济药业有限公司5.66%股权
证券之星 · 11-04
多瑞医药最新公告：拟转让湖北天济药业有限公司5.66%股权
多瑞医药（301075）10月29日主力资金净卖出794.21万元
证券之星 · 10-30
多瑞医药（301075）10月29日主力资金净卖出794.21万元
多瑞医药（301075）2024年三季报简析：净利润减188.44%
证券之星 · 10-26
多瑞医药（301075）2024年三季报简析：净利润减188.44%
多瑞医药(301075.SZ)：醋酸钠林格注射液通过一致性评价
智通财经 · 10-25
多瑞医药(301075.SZ)：醋酸钠林格注射液通过一致性评价
多瑞医药最新公告：子公司药品通过仿制药一致性评价
证券之星 · 10-25
多瑞医药最新公告：子公司药品通过仿制药一致性评价
多瑞医药(301075.SZ)发前三季业绩，净亏损1707.87万元
智通财经 · 10-24
多瑞医药(301075.SZ)发前三季业绩，净亏损1707.87万元
多瑞医药大单品收入腰斩，IPO扩产项目“难产”，过半募资用于理财
时代周报-时代在线 · 10-24
多瑞医药大单品收入腰斩，IPO扩产项目“难产”，过半募资用于理财
多瑞医药（301075）股东西藏嘉康时代科技发展有限公司质押280万股，占总股本3.5%
证券之星 · 10-22
多瑞医药（301075）股东西藏嘉康时代科技发展有限公司质押280万股，占总股本3.5%
多瑞医药(301075.SZ)：氨磺必利注射液药品注册获受理
智通财经 · 10-22
多瑞医药(301075.SZ)：氨磺必利注射液药品注册获受理
多瑞医药拟接手前沿生物“烫手山芋”，近12倍溢价谁笑到最后？
时代周报 · 10-21
多瑞医药拟接手前沿生物“烫手山芋”，近12倍溢价谁笑到最后？
公司概况
公司名称：
西藏多瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-09-29
主营业务：
西藏多瑞医药股份有限公司主要从事化学药品制剂及其原料药的研发、生产和销售业务。公司的主要产品为醋酸钠林格注射液等。
发行价格：
27.27
{"stockData":{"symbol":"301075","market":"SZ","secType":"STK","nameCN":"多瑞医药","latestPrice":18.23,"timestamp":1735110192000,"preClose":19.05,"halted":0,"volume":1659610,"delay":0,"floatShares":80000000,"shares":80000000,"eps":-0.2193,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.82,"latestTime":"12-25 15:00:00","open":19.05,"high":19.13,"low":17.9,"amount":30313600,"amplitude":0.0646,"askPrice":18.23,"askSize":163,"bidPrice":18.22,"bidSize":4,"shortable":0,"etf":0,"ttmEps":-0.2193,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735176600000},"adr":0,"adjPreClose":19.05,"symbolType":"stock","openAndCloseTimeList":[[1735090200000,1735097400000],[1735102800000,1735110000000]],"highLimit":20.96,"lowLimit":17.15,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":80000000,"pbRate":2.11,"roa":"--","roe":"--","epsLYR":0.24,"committee":-0.073746,"marketValue":1458000000,"floatMarketCap":1458000000,"peRate":-83.128134,"changeRate":-0.043,"turnoverRate":0.0207,"status":1},"requestUrl":"/m/hq/s/301075/wiki","defaultTab":"wiki","newsList":[{"id":"2492138159","title":"多瑞医药新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2492138159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492138159?lang=zh_cn&edition=full","pubTime":"2024-12-18 05:15","pubTimestamp":1734470116,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，近日西藏多瑞医药股份有限公司新提交1件商标注册申请。商标申请详情如下：今年以来西藏多瑞医药股份有限公司新申请注册商标4件，截止目前公司共持有注册商标106件，另有12件商标尚在注册申请中。数据来源：企查查以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121800004885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2491865486","title":"多瑞医药最新公告：醋酸钠林格注射液拟中标第十批国家药品集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2491865486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491865486?lang=zh_cn&edition=full","pubTime":"2024-12-16 16:41","pubTimestamp":1734338487,"startTime":"0","endTime":"0","summary":"多瑞医药公告，全资子公司湖北多瑞药业近日参加了第十批国家组织药品集中采购的投标。根据拟中选结果公示，公司产品醋酸钠林格注射液（规格包装500ml/袋）拟中选此次集中采购。公司醋酸钠林格注射液2023年销售收入为2.31亿元，占当期营业收入的69.01%，2024年1—9月销售收入为9228.74万元，占当期营业收入的46.02%，该产品是公司目前核心品种，该产品集中采购拟中选价格及约定采购量预计对公司收入及利润造成较大影响。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121600020934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2491554636","title":"多瑞医药(301075.SZ)：醋酸钠林格注射液拟中选全国药品集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2491554636","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491554636?lang=zh_cn&edition=full","pubTime":"2024-12-16 15:51","pubTimestamp":1734335507,"startTime":"0","endTime":"0","summary":"智通财经APP讯，多瑞医药(301075.SZ)公告，公司全资子公司湖北多瑞药业有限公司近日参加了国家组织药品联合采购办公室组织的第十批国家组织药品集中采购的投标。根据拟中选结果公示，公司产品醋酸钠林格注射液(规格包装500ml/袋)拟中选本次集中采购，碳酸氢钠林格注射液未中选本次集中采购。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225291.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2489323893","title":"多瑞医药（301075）股东西藏嘉康时代科技发展有限公司质押320万股，占总股本4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489323893","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489323893?lang=zh_cn&edition=full","pubTime":"2024-12-06 21:32","pubTimestamp":1733491924,"startTime":"0","endTime":"0","summary":"证券之星消息，多瑞医药12月6日公开信息显示，股东西藏嘉康时代科技发展有限公司向黄平合计质押320.0万股，占总股本4.0%。质押详情见下表：截止本公告日，股东西藏嘉康时代科技发展有限公司已累计质押股份1929.94万股，占其持股总数的41.35%。多瑞医药主营业务：化学药品制剂及其原料药的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120600043845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2484916608","title":"多瑞医药最新公告：全资子公司收到碳酸氢钠注射液药品注册受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2484916608","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484916608?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:20","pubTimestamp":1732011608,"startTime":"0","endTime":"0","summary":"多瑞医药公告，全资子公司湖北多瑞药业有限公司收到国家药品监督管理局下发的碳酸氢钠注射液药品注册受理通知书。该药品主要用于代谢性酸中毒、碱化尿液和静脉滴注对某些药物中毒的治疗等。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111900030762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2484915449","title":"多瑞医药(301075.SZ)：碳酸氢钠注射液药品注册获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2484915449","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484915449?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:11","pubTimestamp":1732011115,"startTime":"0","endTime":"0","summary":"智通财经APP讯，多瑞医药(301075.SZ)公告，公司全资子公司湖北多瑞药业有限公司(简称“湖北多瑞”)收到国家药品监督管理局下发的碳酸氢钠注射液药品注册受理通知书，国家药品监督管理局对上述药品的药品注册申请进行了审查，决定予以受理。碳酸氢钠注射液主要适用于代谢性酸中毒、碱化尿液和静脉滴注对某些药物中毒的治疗等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2481667250","title":"多瑞医药最新公告：四川前沿艾可宁原料药获批上市并通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2481667250","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481667250?lang=zh_cn&edition=full","pubTime":"2024-11-06 19:40","pubTimestamp":1730893231,"startTime":"0","endTime":"0","summary":"多瑞医药公告，控股子公司瑞乐康拟收购的主体四川前沿收到国家药品监督管理局核准签发的《化学原料药上市申请批准通知书》，批准境内生产艾可宁化学原料药的上市申请。同时，四川前沿收到四川省药品监督管理局签发的《药品GMP符合性检查告知书》，艾可宁原料药生产线通过药品GMP符合性检查。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600033603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2481745636","title":"多瑞医药：控股子公司拟收购的四川前沿原料药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2481745636","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481745636?lang=zh_cn&edition=full","pubTime":"2024-11-06 19:33","pubTimestamp":1730892837,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2481674558","title":"多瑞医药(301075.SZ)拟收购主体四川前沿通过药品GMP符合性检查暨原料药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2481674558","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481674558?lang=zh_cn&edition=full","pubTime":"2024-11-06 19:30","pubTimestamp":1730892642,"startTime":"0","endTime":"0","summary":"智通财经APP讯，多瑞医药 发布公告，近日，公司控股子公司昌都市瑞乐康企业管理有限公司拟收购主体四川前沿生物药业有限公司收到国家药品监督管理局核准签发的《化学原料药上市申请批准通知书》，批准境内生产艾可宁化学原料药的上市申请;同时，四川前沿于近日收到四川省药品监督管理局签发的《药品GMP符合性检查告知书》，艾可宁原料药生产线通过药品GMP符合性检查，符合《药品生产质量管理规范》及相关附录规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207625.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2480305379","title":"多瑞医药(301075.SZ)拟以6880万元出售湖北天济5.66%股权 回收资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2480305379","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480305379?lang=zh_cn&edition=full","pubTime":"2024-11-04 17:06","pubTimestamp":1730711214,"startTime":"0","endTime":"0","summary":"智通财经APP讯，多瑞医药(301075.SZ)公告，公司拟将持有的湖北天济药业有限公司(简称“湖北天济”)5.66%股权以合计6880万元人民币转让给湖北青松逾越医药有限公司(简称“青松逾越”)。交易完成后，公司将不再持有湖北天济的股权。该事项有利于公司回收资金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2480837996","title":"多瑞医药最新公告：拟转让湖北天济药业有限公司5.66%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2480837996","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480837996?lang=zh_cn&edition=full","pubTime":"2024-11-04 17:01","pubTimestamp":1730710871,"startTime":"0","endTime":"0","summary":"多瑞医药公告，拟将持有的湖北天济药业有限公司5.66%股权以6880万元转让给湖北青松逾越医药有限公司。交易完成后，公司将不再持有湖北天济的股权。本次交易不构成关联交易，亦不构成重大资产重组。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400021924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2479291239","title":"多瑞医药（301075）10月29日主力资金净卖出794.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479291239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479291239?lang=zh_cn&edition=full","pubTime":"2024-10-30 09:23","pubTimestamp":1730251397,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月29日收盘，多瑞医药报收于20.66元，下跌5.23%，换手率3.34%，成交量2.67万手，成交额5628.89万元。近5日资金流向一览见下表：多瑞医药融资融券信息显示，融资方面，当日融资买入602.93万元，融资偿还594.14万元，融资净买入8.79万元。多瑞医药主营业务：化学药品制剂及其原料药的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000010515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2478998712","title":"多瑞医药（301075）2024年三季报简析：净利润减188.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478998712","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478998712?lang=zh_cn&edition=full","pubTime":"2024-10-26 06:19","pubTimestamp":1729894777,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期多瑞医药发布2024年三季报。根据财报显示，多瑞医药净利润减188.44%。截至本报告期末，公司营业总收入2.01亿元，同比下降18.57%，归母净利润-1707.87万元，同比下降188.44%。去年的净利率为5.11%，算上全部成本后，公司产品或服务的附加值一般。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102600005065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075"],"gpt_icon":0},{"id":"2478882609","title":"多瑞医药(301075.SZ)：醋酸钠林格注射液通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2478882609","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478882609?lang=zh_cn&edition=full","pubTime":"2024-10-25 19:11","pubTimestamp":1729854711,"startTime":"0","endTime":"0","summary":"智通财经APP讯，多瑞医药(301075.SZ)公告，公司全资子公司湖北多瑞药业有限公司(简称“湖北多瑞”)收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，醋酸钠林格注射液(250ml)已通过仿制药质量和疗效一致性评价。醋酸钠林格注射液适用于循环血容量及组织间液减少时细胞外液的补充，代谢性酸中毒的纠正。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1200095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2478408988","title":"多瑞医药最新公告：子公司药品通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2478408988","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478408988?lang=zh_cn&edition=full","pubTime":"2024-10-25 19:10","pubTimestamp":1729854627,"startTime":"0","endTime":"0","summary":"多瑞医药公告，近日，公司全资子公司湖北多瑞药业有限公司收到国家药监局核准签发的《药品补充申请批准通知书》，醋酸钠林格注射液（250ml）已通过仿制药质量和疗效一致性评价。醋酸钠林格注射液适用于循环血容量及组织间液减少时细胞外液的补充，代谢性酸中毒的纠正。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500037298.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2477635223","title":"多瑞医药(301075.SZ)发前三季业绩，净亏损1707.87万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477635223","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477635223?lang=zh_cn&edition=full","pubTime":"2024-10-24 21:10","pubTimestamp":1729775402,"startTime":"0","endTime":"0","summary":"智通财经APP讯，多瑞医药(301075.SZ)发布2024年前三季度报告，报告期内公司实现营业收入2.01亿元，同比减少18.57%;归属于上市公司股东的净亏损1707.87万元;归属于上市公司股东扣除非经常性损益净亏损1968.61万元;基本每股亏损0.21元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1199291.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2477152504","title":"多瑞医药大单品收入腰斩，IPO扩产项目“难产”，过半募资用于理财","url":"https://stock-news.laohu8.com/highlight/detail?id=2477152504","media":"时代周报-时代在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477152504?lang=zh_cn&edition=full","pubTime":"2024-10-24 18:00","pubTimestamp":1729764000,"startTime":"0","endTime":"0","summary":"10月17日，多瑞医药发布的闲置募集资金现金管理进展公告显示，截至公告发布日，多瑞医药使用闲置募集资金进行现金管理未到期余额为2.6亿元，主要用于购买理财产品。IPO项目三年进度不到1%，上半年大单品收入接近腰斩据半年报显示，多瑞医药IPO项目“年产1600万袋醋酸钠林格注射液项目”的募集资金承诺投资总额为2.03亿元，但截至今年上半年末，仅投入了57万元，投资进度为0.28%。近年来多瑞医药的产品销量降幅显著。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-10-24/doc-inctryqx5856238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2477332965","title":"多瑞医药（301075）股东西藏嘉康时代科技发展有限公司质押280万股，占总股本3.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477332965","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477332965?lang=zh_cn&edition=full","pubTime":"2024-10-22 21:29","pubTimestamp":1729603757,"startTime":"0","endTime":"0","summary":"证券之星消息，多瑞医药10月22日公开信息显示，股东西藏嘉康时代科技发展有限公司向黄璐合计质押280.0万股，占总股本3.5%。质押详情见下表：截止本公告日，股东西藏嘉康时代科技发展有限公司已累计质押股份1947.44万股，占其持股总数的41.72%。多瑞医药主营业务：化学药品制剂及其原料药的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102200036192.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2477800787","title":"多瑞医药(301075.SZ)：氨磺必利注射液药品注册获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2477800787","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477800787?lang=zh_cn&edition=full","pubTime":"2024-10-22 17:18","pubTimestamp":1729588691,"startTime":"0","endTime":"0","summary":"智通财经APP讯，多瑞医药(301075.SZ)公告，公司全资子公司湖北多瑞药业有限公司(简称“湖北多瑞”)收到国家药品监督管理局下发的氨磺必利注射液药品注册受理通知书。公告显示，氨磺必利注射液是一种选择性多巴胺-2(D2)和多巴胺-3(D3)受体拮抗剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1197429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2477220861","title":"多瑞医药拟接手前沿生物“烫手山芋”，近12倍溢价谁笑到最后？","url":"https://stock-news.laohu8.com/highlight/detail?id=2477220861","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477220861?lang=zh_cn&edition=full","pubTime":"2024-10-21 22:23","pubTimestamp":1729520598,"startTime":"0","endTime":"0","summary":"本次收购上海建瓴70%股权的对价为7700万元，但需要注意的是，除7700万元对价款外，多瑞医药还需替“四川前沿”向“前沿生物”偿还借款本息余额1.94亿元。因此本次收购，多瑞医药实际支付的价格合计将达2.71亿元。多瑞医药近12倍溢价收购上海建瓴70%股权是否过高？财报显示，多瑞医药主要从事化学药品制剂及其原料药的研发、生产和销售，主要产品为醋酸钠林格注射液。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102122241895b8e474&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102122241895b8e474&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["301075","688221","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-09-29","address":"西藏自治区昌都市卡若区经济技术开发区A区创业大道9号","stockEarnings":[{"period":"1week","weight":-0.0989},{"period":"1month","weight":-0.1086},{"period":"3month","weight":0.0393},{"period":"6month","weight":0.1465},{"period":"1year","weight":-0.2816},{"period":"ytd","weight":-0.3117}],"companyName":"西藏多瑞医药股份有限公司","boardCode":"AI0027","perCapita":"8672股","boardName":"医药制造业","registeredCapital":"8000万元","compareEarnings":[{"period":"1week","weight":0.0033},{"period":"1month","weight":0.0397},{"period":"3month","weight":0.1308},{"period":"6month","weight":0.1435},{"period":"1year","weight":0.1706},{"period":"ytd","weight":0.1406}],"survey":" 西藏多瑞医药股份有限公司主要从事化学药品制剂及其原料药的研发、生产和销售业务。公司的主要产品为醋酸钠林格注射液等。","serverTime":1735173032594,"listedPrice":27.27,"stockholders":"9225人(较上一季度减少0.26%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"多瑞医药(301075)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供多瑞医药(301075)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"多瑞医药,301075,多瑞医药股票,多瑞医药股票老虎,多瑞医药股票老虎国际,多瑞医药行情,多瑞医药股票行情,多瑞医药股价,多瑞医药股市,多瑞医药股票价格,多瑞医药股票交易,多瑞医药股票购买,多瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"多瑞医药(301075)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供多瑞医药(301075)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}